Tipranavir exhibits different effects on opportunistic pathogenic fungi

Journal of Infection

Volumn 56, Issue 1, 2008, Pages 58-64

  Cenci, Elio ^a   Francisci, Daniela ^a   Belfiori, Barbara ^a   Pierucci, Sara ^a   Baldelli, Franco ^a   Bistoni, Francesco ^a   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

AIDS; Candida albicans; Cryptococcus neoformans; Fungi; HIV; Opportunistic pathogens; Protease inhibitors; Tipranavir

Indexed keywords

INDINAVIR; PHOSPHOLIPASE; PROTEINASE; TIPRANAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG MECHANISM; FUNGAL COLONIZATION; FUNGAL VIRULENCE; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCELIUM; MYCOSIS; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; BRAIN; CANDIDA ALBICANS; CELL WALL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; LIVER; MICE; MICE, INBRED BALB C; MYCELIUM; NEUTROPHILS; PEPTIDE HYDROLASES; PHAGOCYTOSIS; PHOSPHOLIPASES; PYRIDINES; PYRONES; STEM CELLS; VIRULENCE;

EID: 37149042967     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.08.004     Document Type: Article

References (26)

1. Hicks C.B., Cahn P., Cooper D.A., Walmsley S.L., Katlama C., Clotet B., et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
2. DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents; 2006.
3. Cassone A., De Bernardis F., Torosantucci A., Tacconelli E., Tumbarello M., and Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180 (1999) 448-453
4. Borg-von Zepelin M., Meyer I., Thomssen R., Wurzner R., Sanglard D., Telenti A., et al. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113 (1999) 747-751
5. Bobin S., Bouhour D., Durupt S., Boibieux A., Girault V., and Peyramond D. Importance of antiproteases in the treatment of microsporidia and/or cryptosporidia infections in HIV-seropositive patients. Pathol Biol (Paris) 46 (1998) 418-419
6. Murphy R. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 study. Program and abstracts of the fifth conference on retroviruses and opportunistic infections (1998), Foundation for Retrovirolgy and Human Health, Alexandria, VA 113 [abstract 181]
7. Monari C., Pericolini E., Bistoni G., Cenci E., Bistoni F., and Vecchiarelli A. Influence of indinavir on virulence and growth of Cryptococcus neoformans. J Infect Dis 191 (2005) 307-311
8. Blasi E., Colombari B., Orsi C.F., Pinti M., Troiano L., Cossarizza A., et al. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. FEMS Immunol Med Microbiol 42 (2004) 187-195
9. Bistoni F., Vecchiarelli A., Cenci E., Puccetti P., Marconi P., and Cassone A. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 51 (1986) 668-674
10. Charney J., and Tomarelli R.M. A colorimetric method for the determination of the proteolytic activity of duodenal juice. J Biol Chem 171 (1947) 501-505
11. Echevarria A., Durante A.G., Arechaval A., and Negroni R. Comparative study of two culture media for the detection of phospholipase activity of Candida albicans and Cryptococcus neoformans strains. Rev Iberoam Micol 19 (2002) 95-98
12. Franzot S.P., Mukherjee J., Cherniak R., Chen L.C., Hamdan J.S., and Casadevall A. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun 66 (1998) 89-97
13. Zuluaga A.F., Salazar B.E., Rodriguez C.A., Zapata A.X., Agudelo M., and Vesga O. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 6 (2006) 55
14. Gauthier S.A., and Weiner H.L. Cyclophosphamide therapy for MS. Int MS J 12 (2005) 52-58
15. Cahn P., Villacian J., Lazzarin A., Katlama C., Grinsztejn B., Arasteh K., et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 43 (2006) 1347-1356
16. Pericolini E., Cenci E., Monari C., Perito S., Mosci P., Bistoni G., et al. Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts. Med Mycol 44 (2006) 119-126
17. Buchanan K.L., and Murphy J.W. What makes Cryptococcus neoformans a pathogen?. Emerg Infect Dis 4 (1998) 71-83
18. Schaller M., Korting H.C., Borelli C., Hamm G., and Hube B. Candida albicans-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. Infect Immun 73 (2005) 2758-2765
19. Albrecht A., Felk A., Pichova I., Naglik J.R., Schaller M., de Groot P., et al. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 281 (2006) 688-694
20. De Bernardis F., Boccanera M., Adriani D., Spreghini E., Santoni G., and Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 65 (1997) 3399-3405
21. de Bernardis F., Mondello F., Scaravelli G., Pachi A., Girolamo A., Agatensi L., et al. High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women. J Clin Microbiol 37 (1999) 1376-1380
22. Casadevall A., Steenbergen J.N., and Nosanchuk J.D. 'Ready made' virulence and 'dual use' virulence factors in pathogenic environmental fungi - the Cryptococcus neoformans paradigm. Curr Opin Microbiol 6 (2003) 332-337
23. Chang Z.L., Netski D., Thorkildson P., and Kozel T.R. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages. Infect Immun 74 (2006) 144-151
24. Feldmesser M., Tucker S., and Casadevall A. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 9 (2001) 273-278
25. Shea J.M., Kechichian T.B., Luberto C., and Del Poeta M. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun 74 (2006) 5977-5988
26. Casadevall A., and Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr Mol Med 5 (2005) 421-433